A Phase 1 single ascending dose study of a novel orexin 2...

Sleep Medicine 2019 / 12 Vol. 64

A Phase 1 single ascending dose study of a novel orexin 2 receptor agonist, TAK-925, in healthy volunteers (HV) and subjects with narcolepsy type 1 (NT1) to assess safety, tolerability, pharmacokinetics, and pharmacodynamic outcomes

Evans, R., Tanaka, S., Tanaka, S., Touno, S., Shimizu, K., Sakui, S., Wu, J., Faessel, H., Hang, Y., Alexander, R., Rosen, L., Hartman, D.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
64
Journal:
Sleep Medicine
DOI:
10.1016/j.sleep.2019.11.290
Date:
December, 2019
File:
PDF, 68 KB
2019
Conversion to is in progress
Conversion to is failed